preprotein

— The strategies have been focused on production of stronger statins, MTP inhibitors such as Lomitapide, ACAT2 inhibitors, cholesteryl ester transfer protein (CETP) inhibitors such as Torcetrapib, Anacetrapib, Evacetrapib, and Dalcetrapib, antioxidants, squalene synthase inhibitors, preprotein convertase subtilisin kexin-9 inhibitors (PCSK9) such as Regeneron®, selective thyroid hormone mimetics such as Sobetirome as a β-receptor agonist, combination form of PPAR-α and γ agonists (Aleglitazar), PPAR-δ agonists (GW501516), and Apo A-I agonists (CSL-112) [ 116, 118 ].